UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Authors*: Igor I. Rybkin, Ebenezer A. Kio, Ashiq Masood, Merrill Kingman Shum, Balazs Halmos, Collin M. Blakely, Keith D. Eaton, Neelesh Sharma, John J. Nemunaitis, Steven J. Saccaro, Yanis Boumber, Raul R. Mena, Hamid R. Mirshahidi, Pasi A. Janne, James Christensen, Richard C. Chao, Vanessa Roberts Tassell, Demiana Faltaos, Marshall T. Schreeder Abstract #: TPS9099 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #422a Session: Lung Cancer - Non-Small Cell Metastatic Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS9099) __________________________________________________________________________ TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. Authors*: James Chih-Hsin Yang, Sanjay Popat, Silvia Novello, Harry J.M. Groen, Maurice Perol, Enriqueta Felip, Frank Griesinger, Karen L. Reckamp, Jong-Seok Lee, Egbert F. Smit, Collin M. Blakely, Wallace L. Akerley, Young-Chul Kim, Lyudmila Bazhenova, Raffaele Califano, Richard Delmar Hall, Panayiotis Georgiou, Jeffrey D. Isaacson, Tony Golsorkhi, Heather A. Wakelee Abstract #: TPS9106 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board 425b Session: Lung Cancer - Non-Small Cell Metastatic Citation: J Clin Oncol 34, 2016 (suppl; abstr TPS9106) *UCSF authors in bold 16
Presentations Genomic Profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. Authors*: Emily K. Bergsland, Ritu Roy, Phil Stephens, Jeffrey S. Ross, Mark Bailey, Adam Olshen Abstract #: 4020 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #12 Poster Session: Gastrointestinal (Noncolorectal) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 4020) Bergsland Research Interests: My research is focused on the development and testing of novel, biologically based therapies for gastrointestinal malignancies, with an emphasis on neuroendocrine tumors (NETs). I am co-chair of the Neuroendocrine Tumor Task Force of the NCI Gastrointestinal Steering Committee, a NCCN Neuroendocrine Tumors Guidelines Panel member, Board of Directors member for NANETS, and co-chair of the 8th edition AJCC Expert Panel on staging for NETs. I am study chair for ALLIANCE A021202 (an ongoing randomized Phase II trial of pazopanib vs. placebo in patients with progressive carcinoid tumors). My current research focuses on data from three completed investigator-initiated Phase II clinical trials in NETs (a. FOLFOX/bevacizumab, b. everolimus plus erlotinib, and c. axitinib), fostering several collaborations with laboratory-based colleagues, and taking advantage of a fully annotated outcomes database (established in 2010 and encompassing 600+ NET patients treated at UCSF since 2004). http://cancer.ucsf.edu/gi/emily-bergsland __________________________________________________________________________ Head and Neck Cancer Updates from the American Society for Radiation Oncology Authors*: Sue Sun Yom Abstract #: Presentation Date/Time: Saturday, June 4: 8:20 - 8:40 AM Location: S100bc Education Session: Best of the Rest: Top Abstracts on Head and Neck Cancer from the 2015-2016 Oncology Meetings Citation: Yom Research Interests: Dr. Yom is an expert in head and neck, thoracic, and skin cancers and conducts research in quality of life and supportive care, patient-oriented decision making, and combinations of novel targeted therapies and immunotherapy with radiation therapy. She is the principal investigator of HN002, a national trial in de-intensified therapy for HPV+ oropharyngeal cancer. She serves on several national panels developing guidelines for appropriate care of head and neck cancers. http://profiles.ucsf.edu/sue.yom *UCSF authors in bold 17
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9 and 10: Presentations Phase II trials of ce
Page 11 and 12: Presentations CRS-207 immunotherapy
Page 13 and 14: Presentations Long-term OS for pati
Page 15: Presentations Randomized phase 2 st
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62: Presentations A phase 2 randomized,
Page 63 and 64: Presentations PD-L1 expression, Can
Page 65 and 66: Presentations The Heart of the Matt
Page 67 and 68:
Presentations 4-year results of the
Page 69 and 70:
Presentations Impact of landmark re
Page 71 and 72:
Presentations Phase II study of ali
Page 73 and 74:
Presentations Can lay health worker
Page 75 and 76:
Presentations Medical Management of
Page 77 and 78:
Presentations Prospective evaluatio
Page 79 and 80:
Presentations A phase II randomized
Page 81 and 82:
Presentations Early, molecular dete
Page 83 and 84:
Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?